Epidural hematoma after total knee arthroplasty in a patient receiving rivaroxaban: A case report
Anesthesia and Pain Medicine
;
: 102-105, 2019.
Artículo
en Inglés
| WPRIM
| ID: wpr-719395
ABSTRACT
Rivaroxaban, a factor Xa inhibitor, is one of the newly developed direct oral anticoagulants (DOAC). In recent times, it has been increasingly used in the prevention of pulmonary embolism in patients undergoing orthopedic surgery. This report describes a case of epidural hematoma in an elderly patient who underwent combined spinal epidural anesthesia for total knee arthroplasty; the patient received rivaroxaban postoperatively for 7 days to prevent pulmonary embolism. Additionally, the epidural hematomas developed on the 5th postoperative day but the patient recovered well with conservative treatment. Although rivaroxaban has a low need for monitoring and is easily administered, the guidelines should be carefully checked for the postoperative administration schedule in patients undergoing regional anesthesia. In addition, rivaroxaban should be used with caution, especially in elderly patients.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Ortopedia
/
Citas y Horarios
/
Embolia Pulmonar
/
Factor Xa
/
Artroplastia de Reemplazo de Rodilla
/
Hematoma Espinal Epidural
/
Rivaroxabán
/
Hematoma
/
Anestesia de Conducción
/
Anestesia Epidural
Tipo de estudio:
Guía de Práctica Clínica
Límite:
Anciano
/
Humanos
Idioma:
Inglés
Revista:
Anesthesia and Pain Medicine
Año:
2019
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS